The Easy Book of Cancer Pharmacology

Esther Una Cidon (Editor)
Medical Oncology Department, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, United Kingdom

Series: Cancer Etiology, Diagnosis and Treatments, Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$210.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The Easy Book of Cancer Pharmacology represents the efforts of young oncologists, haematologists, pharmacists and oncology nurses who are highly motivated and encouraged by the significant development of new effective anticancer drugs. Since the discovery of antimetabolites and alkylating agents in the 1940s and 1950s, many new products have been introduced into our daily arsenal not only through chemotherapy agents, but also by means of biological or immunotherapeutic drugs whose side effects differ significantly.

The idea of this book was born from a simple observation and confirmation of fact. New doctors in training experience high levels of stress and lack of confidence when confronting cancer patients and explaining a treatment or managing frequent side effects. Patients’ questions will only add more nervousness, and this will lead to a failure in the doctor-patient relationship, causing the patient’s mistrust and doctor’s frustration. Nurses dealing with these patients will suffer pressure too, as many questions regarding antineoplastic drugs will be asked of them and patients expect them to ease their doubts. This feeling of vulnerability in front of a patient, though a part of the maturation process when becoming a professional caretaker, causes discomfort and incertitude.

In this context, it is crucial to gain great knowledge about pharmacokinetic and pharmacological features of each active anticancer drug used, as well as the indications, dosages, interactions and toxicities, to be able to face the daily practice of oncology without concerns and manage daily therapeutic complications easily.

This may be considered very difficult, taking into account the huge number of active agents doctors manage routinely, but doctors have accepted the challenge and designed a straightforward, comprehensible book to solve this issue. The Easy Book of Cancer Pharmacology provides the means to overcome the problem. It is conceived as an accessible, concise and yet exhaustive tool which displays a vast amounts of knowledge in a very schematic way. It is easy to consult and offers a very practical expertise to develop the ability of managing effectively each antineoplastic agent quickly. It gives the necessary insights to explain this to the patients with confidence.

Each chapter reviews one active drug and shows the information with a pragmatic style, and they are divided into different sections. Each section covers distinct aspects of the agent, from general characteristics to more specific details related to clinical pharmacology. In quickly advancing fields such as oncology, such a book is necessary to help update the ever-developing and expanding knowledge of clinicians and patients in an efficient and effective manner. (Imprint: Nova Biomedical)

Foreword

Preface

Chapter 1. Abiraterone. Abiraterone Acetate. CB7630. Zytiga®
A.Ballesteros (Directorate Pharmacist, Oncology, Poole Hospital Foundation Trust, Poole, UK)

Chapter 2. Albumin-Bound (NAB) Paclitaxel, Abraxane®
V. Arrazubi, E. Galve, P. Martínez del Prado (Medical Oncology Department. Basurto University Hospital. Bilbao, Spain)

Chapter 3. Aflibercept. Zaltrap®
M. López-Gómez, B. García de Santiago, E. Jiménez, A.M. Jiménez-Gordo, E. Casado (Medical Oncology Department, University Hospital “Infanta Sofia”, Madrid, Spain)

Chapter 4. Axitinib. Inlyta®
A. Ballesteros (Directorate Pharmacist, Oncology. Poole Hospital Foundation Trust, Poole, UK)

Chapter 5. Bevacizumab. Avastin
M. López-Gómez, B. García de Santiago, A. I. García, A.M. Jiménez-Gordo, E. Casado (Medical Oncology Department, University Hospital “Infanta Sofia”, Madrid, Spain)

Chapter 6. Bleomycin. Bleo-kyowa. Blenoxane
B. Masters (Specialist Registrar in Clinical Oncology, Nottingham City Hospital, Nottingham, UK)

Chapter 7. Cabazitaxel. Jevtana®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 8. Cabozantinib (XL184). Cometriq®
J. Molina Cerrillo, M. Gion Cortes, T. Gordoa Alonso, E. Grande-Pulido (Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain)

Chapter 9. Capecitabina. Xeloda®
P. Diezhandino and P. Alonso (Radiotherapy oncology service. Clinical Universitary Hospital. Valladolid. Spain)

Chapter 10. Carboplatin. Paraplatin®. CBDCA. Diammineplatinum (II). CIS-(1,1.Cyclobutanedicarboxylato). CIS-Diammine (1,1-Cyclobutanediocarboxylato) Platinum
M. Luque Cabal and P. Garcia Teijido (Medical Oncology Department, University Hospital of Asturias, Oviedo, Spain. 2Medical Oncology Department, “San Agustin” Hospital, Aviles, Spain)

Chapter 11. Cetuximab. Erbitux®
M. López-Gómez, B. García de Santiago, Y. Martín, A.M. Jiménez-Gordo, E. Casado (Medical Oncology Department, University Hospital “Infanta Sofia”, Madrid, Spain)

Chapter 12. Cisplatin, Platinol®, Platinol®-AQ
M. Luque Cabal, P. Garcia Teijido (Medical Oncology Department, University Hospital of Asturias, Oviedo, Spain. 2Medical Oncology Department, “San Agustin” Hospital, Aviles, Spain)

Chapter 13. Crizotinib. Xalkori ®
V. Wood (Clinical Oncology, University Hospital Southampton. Southampton, UK)

Chapter 14. Cytarabine. ARA-C. Cytosar U. Cytosine arabinoside. Tarabine PFS, Arabinosylcytosine, 1- β-Arabinosylcytosine
T. Cummin (Haematology Department, Poole Hospital NHS Foundation Trust, Poole, UK)

Chapter 15. Denosumab, Prolia®, Xgeva®
P. Alonso, P. Diezhandino (Radiotherapy oncology service. Clinical University Hospital. Valladolid. Spain)

Chapter 16. Docetaxel.Taxotere®
E. Galve, V. Arrazubi, P. Martínez del Prado, E. Una Cidon (Medical Oncology Department. Basurto University Hospital. Bilbao, Spain. 2Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust (UK))

Chapter 17. Doxorubicin hydrochloride. Adriamycin
Z. Anwar (Oncology Department, Poole Hospital NHS Foundation Trust, Poole, UK)

Chapter 18. Enzalutamide. Xtandi®. MVD3100
J. Ching (Clinical Oncology Department, Poole Hospital NHS Foundation Trust, Poole, UK)

Chapter 19. Erlotinib, Tarceva®
S. Adeleke (Clinical Research Fellow, Clinical Research Facility, University College Hospital, London, UK)

Chapter 20. Etoposide. VP16. Vepesid. Etopophos
Z. Anwar (Oncology Department, Poole Hospital NHS Foundation Trust, Poole, UK)

Chapter 21. Everolimus. Afinitor®
Y. Inam (Oncology Department, Royal Bournemouth Hospital, Bournemouth, UK)

Chapter 22. Gefitinib
S. Adeleke (Clinical Research Fellow, Clinical Research Facility, University College Hospital, London, UK)

Chapter 23. Gemcitabine. Gemzar®
P. Martínez del Prado, E. Galve, V. Arrazubi (Medical Oncology Department. Basurto University Hospital. Bilbao, Spain)

Chapter 24. Imatinib. Gleevec®
A. Ballesteros (Directorate Pharmacist, Oncology. Poole Hospital Foundation Trust, Poole, UK)

Chapter 25. Ipilimumab
J. Fra (Oncology Unit. University Hospital Río Hortega. Valladolid. Spain)

Chapter 26. Irinotecan. CPT-11. Camptosar®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 27. Lapatinib
V. Reguero Cuervo1, T. Sampedro Gimeno, P. García Teijido (Hospital of Cabueñes. Gijón, Spain; Hospital San Agustín. Avilés. Spain)

Chapter 28. Lenvatinib, Lenvima®
O. Martínez-Sáez, A. Madariaga-Urrutia, T. Alonso-Gordoa, E. Grande (Medical Oncology Department, Ramón y Cajal University Hospital)

Chapter 29. Mitomycin C Mitomycin-C Kyowa [3], Mutamycin, Ametycine, Mitocin-C, Mitolem, Mito-Medac [1] Mitosol [12] M. Uherek (University Hospital Southampton NHS Foundation Trust, Southampton, UK)

Chapter 30. Nindetanib. Vargatef®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 31. Nivolumab. Opdivo®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 32. Oxaliplatin. 1-OHP, L-OHP, Oxalatoplatin, Oxaliplatinum, Eloxatin®
M. Luque Cabal and P. Garcia Teijido (Medical Oncology Department, University Hospital of Asturias, Oviedo, Spain. Medical Oncology Department, “San Agustin” Hospital, Aviles, Spain)

Chapter 33. Paclitaxel. Taxol
E. Una Cidon and A. Ballesteros (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK. Directorate Pharmacist, Oncology. Poole Hospital Foundation Trust, Poole, UK)

Chapter 34. Panitumumab. Vectibix®
M. López-Gómez, B. García de Santiago, R. Hernández, A.M. Jiménez-Gordo, E. Casado (Medical Oncology Department, University Hospital “Infanta Sofia”, Madrid, Spain)

Chapter 35. Pazopanib. Votrient®
A.Hernandez-Sanchez (Pharmacy Department, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK)

Chapter 36. Pembrolizumab. Keytruda®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 37. Pemetrexed. Alimta®
M. Uherek (University Hospital Southampton NHS Foundation Trust, Southampton, UK)

Chapter 38. Pertuzumab. Perjeta®
T. Sampedro Gimeno, V. Reguero Cuervo1, P. Garcia-Teijido (Department of Medical Oncology, Cabueñes Hospital, Gijon, Spain. 2 Department of Medical Oncology, “San Agustín” Hospital, Aviles, Spain)

Chapter 39. Regorafenib. Stivarga®
M. López-Gómez, B. García de Santiago, C. Martín, M Caridad Miguel, E. Casado (Medical Oncology Department, University Hospital “Infanta Sofia”, Madrid, Spain)

Chapter 40. Sorafenib, Nexavar®
E. Una Cidon (Department of Medical Oncology. Royal Bournemouth Hospital NHS Foundation Trust, UK)

Chapter 41. Streptozocin. Zanosar®
V. Wood (Clinical Oncology, University Hospital Southampton. Southampton, UK)

Chapter 42. Sunitinib. Sutent®
S. Adeleke (Clinical Research Fellow, Clinical Research Facility, University College Hospital, London, UK)

Chapter 43. Trastuzumab Emtansine (TDM-1)
P. Garcia-Teijido, T. Sampedro Gimeno, V. Reguero Cuervo, M.Luque Cabal (Hospital San Agustín, Spain; Hospital de Cabueñes, Spain; Central University Hospital Asturias)

Chapter 44. Temozolomide. Temodal®. Temodar®. SCHS2.365. NSC 362856
J. Ching (Clinical Oncology Department, Poole Hospital NHS Foundation Trust, Poole, UK)

Chapter 45. Temsirolimus. CCI-779. Torisel®
J.M. Roca (Medical Oncology, Guy’s Hospital, London, UK)

Chapter 46. Topotecan, Hycamtin®
J.M. Roca (Medical Oncology, Guy’s Hospital, London, UK)

Chapter 47. Trastuzumab. Herceptin®
P. Garcia-Teijido, T. Sampedro Gimeno, V. Reguero Cuervo, M. Luque Cabal (Hospital San Agustín, Spain; Hospital Cabueñes, Spain; Central University Hospital of Oviedo, Spain)

Chapter 48. Vandetanib (ZD 6474). Caprelsa
P. Reguera Puertas, M. Villamayor Delgado, T. Alonso Gordoa, E Grande Pulido (Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain)

Chapter 49. Vemurafenib. Zelboraf®
A. Hernandez-Sanchez (Pharmacy Department. Royal Bournemouth and Christchurch NHS Foundation Trust)

Chapter 50. Vinorelbine. Navelbine®
B. Masters (Specialist Registrar in Clinical Oncology, Nottingham City Hospital, Nottingham, UK)

Chapter 51. Zoledronic Acid, Zometa®, Aclasta®, Reclast®
P. Alonso, P. Diezhandino (Radiotherapy oncology service. Clinical University Hospital. Valladolid. Spain)

Chapter 52. 5-Fluorouracil, 5-Fluracil, Fluorouracil, FU
P. Diezhandino1, P. Alonso (Radiotherapy oncology service. Clinical University Hospital. Valladolid. Spain)

Editor's Contact Information

Index

You have not viewed any product yet.